The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies

Blood

Volumn 122, Issue 3, 2013, Pages 424-433

  Liapis, Konstantinos ^a   Clear, Andrew ^a   Owen, Andrew ^a,b   Coutinho, Rita ^a   Greaves, Paul ^a   Lee, Abigail M ^a,b   Montoto, Silvia ^a   Calaminici, Maria ^a,b   Gribben, John G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIGEN P24; CD163 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; GRANZYME B; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; LANA1 PROTEIN; LATENT MEMBRANE PROTEIN 1; MYC PROTEIN; PERFORIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; RITUXIMAB; SYNDECAN 1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VIRAL PROTEIN; TUMOR MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CAPILLARY DENSITY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INTERNATIONAL PROGNOSTIC INDEX; LYMPHOCYTIC INFILTRATION; MALE; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; VIRUS EXPRESSION; AGED; B CELL LYMPHOMA; BLOOD VESSEL; CELL AGING; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LARGE CELL LYMPHOMA; MACROPHAGE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; VERY ELDERLY; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; BLOOD VESSELS; CELL AGING; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE REARRANGEMENT; HERPESVIRUS 4, HUMAN; HIV-1; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE B-CELL, DIFFUSE; MACROPHAGES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84884598240     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-488171     Document Type: Article

References (39)

1. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92(22): 1823-1830.
2. Bonnet F, Lewden C, May T, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004;101(2):317-324.
3. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist. 2005;10(6):412-426.
4. Tirelli U, Bernardi D. Impact of HAART on the clinical management of AIDS-related cancers. Eur J Cancer. 2001;37(10):1320-1324.
5. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370(9581):59-67.
6. Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012;119(14): 3245-3255.
7. Stebbing J, Gazzard B, Douek DC. Where does HIV live? N Engl J Med. 2004;350(18): 1872-1880.
8. Lenz G, Wright G, Dave SS, et al; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22): 2313-2323.
9. Perry AM, Cardesa-Salzmann TM, Meyer PN, et al. A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2012;120(11):2290-2296.
10. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
11. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006; 8(2):141-151.
12. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8.
13. Clear AJ, Lee AM, Calaminici M, et al. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD1631 macrophages within the immediate sprouting microenvironment. Blood. 2010;115(24): 5053-5056.
14. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
15. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001;97(3): 744-751.
16. Podack ER. Execution and suicide: cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways. Curr Opin Immunol. 1995;7(1):11-16.
17. Kamarashev J, Burg G, Mingari MC, Kempf W, Hofbauer G, Dummer R. Differential expression of cytotoxic molecules and killer cell inhibitory receptors in CD81 and CD561 cutaneous lymphomas. Am J Pathol. 2001;158(5): 1593-1598.
18. Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med. 2005;143(4):265-273.
19. Porcheray F, Samah B, Léone C, Dereuddre-Bosquet N, Gras G. Macrophage activation and human immunodeficiency virus infection: HIV replication directs macrophages towards a pro-inflammatory phenotype while previous activation modulates macrophage susceptibility to infection and viral production. Virology. 2006;349(1): 112-120.
20. Moses AV, Williams SE, Strussenberg JG, et al. HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphomas. Nat Med. 1997; 3(11):1242-1249.
21. Chirivi RG, Taraboletti G, Bani MR, et al. Human immunodeficiency virus-1 (HIV-1)-Tat protein promotes migration of acquired immunodeficiency syndrome-related lymphoma cells and enhances their adhesion to endothelial cells. Blood. 1999; 94(5):1747-1754.
22. Li JC, Yim HC, Lau AS. Role of HIV-1 Tat in AIDS pathogenesis: its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection. AIDS. 2010;24(11):1609-1623.
23. De Falco G, Bellan C, Lazzi S, et al. Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene. 2003;22(40): 6214-6219.
24. Huysentruyt LC, McGrath MS. The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma. J Leukoc Biol. 2010;87(4): 627-632.
25. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006; 439(7077):682-687.
26. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9): 1612-1621.
27. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD81 T cells. Blood. 2003;101(7): 2711-2720.
28. Rosenberg YJ, Zack PM, Leon EC, et al. Immunological and virological changes associated with decline in CD4/CD8 ratios in lymphoid organs of SIV-infected macaques. AIDS Res Hum Retroviruses. 1994;10(7): 863-872.
29. Sopper S, Nierwetberg D, Halbach A, et al. Impact of simian immunodeficiency virus (SIV) infection on lymphocyte numbers and T-cell turnover in different organs of rhesus monkeys. Blood. 2003; 101(4):1213-1219.
30. Shair KH, Bendt KM, Edwards RH, Bedford EC, Nielsen JN, Raab-Traub N. EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog. 2007;3(11): e166.
31. Kondo S, Seo SY, Yoshizaki T, et al. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res. 2006;66(20): 9870-9877.
32. Hong GK, Kumar P, Wang L, et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol. 2005;79(22): 13984-13992.
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5): 646-674.
34. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi’s sarcoma. Nature. 1994;371(6499):674-680.
35. Uldrick TS, Wyvill KM, Kumar P, et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi’s sarcoma receiving antiretroviral therapy. J Clin Oncol. 2012;30(13): 1476-1483.
36. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi’s sarcoma and tumour growth. Lancet Oncol. 2003;4(9): 537-547.
37. Zhang B, Kracker S, Yasuda T, et al. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell. 2012;148(4): 739-751.
38. Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4(1) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637-650.
39. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26): 2455-2465.